<DOC>
	<DOCNO>NCT02336048</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize , placebo-controlled study evaluate safety single infusion tocilizumab versus placebo , administer addition standard premedications ( antipyretic , antihistamine , corticosteroid ) prior first infusion obinutuzumab administer combination oral chlorambucil participant previously untreated B-CLL comorbidities . All eligible participant treat total 6 cycle obinutuzumab + chlorambucil ( cycle length = 28 day ) .</brief_summary>
	<brief_title>A Study Evaluating Safety Tocilizumab Addition Standard Care Premedication Given Before Obinutuzumab + Chlorambucil Participants With Untreated B-Cell Chronic Lymphocytic Leukemia ( B-CLL ) Comorbidities</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Documented cluster differentiation ( CD ) 20+ BCLL accord NCI/IWCLL guideline Total Cumulative Illness Rating Scale ( CIRS ) score great ( &gt; ) 6 and/or creatinine clearance less ( &lt; ) 70 milliliter per minute ( mL/min ) Previously untreated chronic lymphocytic leukemia ( CLL ) require treatment accord NCI/IWCLL guideline warrant treatment protocolspecified comorbidities Life expectancy &gt; 6 month Adequate hematological function , unless abnormality cause underlying CLL Agreement use highly effective contraceptive measure per protocol Any previous CLL treatment Documented transformation CLL aggressive nonHodgkin 's lymphoma ( Richter 's transformation ) Abnormal laboratory test value , unless abnormality cause underlying CLL History progressive multifocal leukoencephalopathy Previous treatment tocilizumab indication History severe allergic anaphylactic reaction monoclonal antibody therapy Known hypersensitivity study drug History prior malignancy unless malignancy treat curative intent remission without treatment least ( &gt; /= ) 5 year prior enrollment exception curativelytreated basal squamous cell carcinoma skin , low grade situ carcinoma cervix , low grade early stage localize prostate cancer treat surgically curative intent ductal carcinoma situ breast treat lumpectomy alone Treatment glucocorticoid dose ( except topical formulation ) 2 week prior start Cycle 1 Day 1 . Regular treatment glucocorticoid ( &gt; 5 day duration ) also prohibit 4week screening period Ongoing treatment immunosuppressive medication antitumor necrosis factor biologic therapy Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular pulmonary disease Known active history recurrent bacterial , viral , fungal , mycobacterial , parasitic , infection ( exclude fungal infection nail bed ) require treatment intravenous ( IV ) antibiotic hospitalization within 4 week prior start Cycle 1 Day 1 Active tuberculosis ( TB ) require treatment within 3 year prior baseline latent TB diagnose screen appropriately treat Vaccination live attenuate vaccine within 28 day prior start treatment Major surgery ( within 4 week prior Cycle 1 Day 1 ) , diagnosis Positive test result chronic hepatitis B infection positivity hepatitis B core antibody Positive test result hepatitis C Known history human immunodeficiency virus ( HIV ) seropositive status Positive test result human Tlymphotropic virus 1 ( HTLV 1 ) Pregnant lactate woman Participation another clinical study drug intervention unless last dose administer great 5 halflives study product prior study start Any participant actively take antiplatelet medication participant fully anticoagulated warfarin , lowmolecular weight heparin novel oral anticoagulant include dabigatran , rivaroxiban , epixiban , similar Previous treatment Bcell deplete agent Any inherit bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>